GPCRs form one of the most important classes of drug targets, and Heptares is the world leader in the use of structure-based methods for GPCR drug discovery. leadXpro
SAP302 is a single-arm, open-label study that enrolled 76 adult patients who presented in the emergency room with moderate-to-severe acute pain associated with trauma or injury. The primary
Merck will provide funding and expertise in the areas of clarification and purification. The IVI is a nonprofit international organization committed to the discovery, development and delivery of
Participants included Batterson Venture Capital, VCapital, FastForward Innovations, SalvaRx Group PLC, Declan Doogan M.D. and Jim Mellon as well as several other accredited investors and family offices. "Our
This achievement follows Kitov’s announcement in May 2016 that Dexcel completed manufacturing pivotal batches of KIT-302. Stability is a critical quality attribute of pharmaceutical products, and stability studies
In March 2016, Onxeo successfully completed the acquisition of DNA Therapeutics for its key innovative DNA repair inhibitor technology platform and lead compound AsiDNA. Following the acquisition, Onxeo
Elocta is the only recombinant factor VIII Fc fusion protein with an extended half-life approved for haemophilia A treatment in Switzerland to offer prolonged protection against bleeding episodes
As part of the Breakthrough Therapy Designation submission, the Company shared for the FDA’s review results from Phase 2 study CA209-275 and other supportive data investigating Opdivo in
A further dose range finding study will be implemented prior to proceeding into the planned pivotal Phase III study. GrassMATAMPL is an ultra-short course subcutaneous allergen specific immunotherapy
Streamlining of the REMS process is not due to any change in the risk of Sabril-induced permanent vision loss. The Sabril REMS program, formerly known as SHARE, has
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.